The University of Zimbabwe-University of California, San Francisco Collaborative Research Programme (UZUCSF), in collaboration with the University of California, San Francisco (UCSF), is the site of a well-established, large Clinical Trials Unit (CTU) with 4 Clinical Research Sites (CRSs), covering 6 distinct geographic locations within and surrounding Harare, Zimbabwe. Experience gained from leadership and participation in 4 Division of AIDS (DAIDS) Networks (HPTN, MTN, ACTG, IMPAACT), positions the CTU to continue its contribution to the global understanding of HIV epidemiology and pathogenesis by serving as a center of research excellence in the prevention and control of HIV and AIDS. Utilizing the expertise of our international and local complement of investigators and highly trained and experienced research personnel, the CTU will accomplish this through completion of the following Specific Aims: 1.a. Identifying, screening, enrolling, and retaining existing and new at-risk populations in an environment of declining prevalence and incidence, in the following mission-specific domains of scientific priority of the 4 future NIAID-sponsored Networks: i) Adult HIV Therapeutic Strategies, including HIV cure, noninfectious comorbidities, and the infectious co-morbidities of hepatitis and tuberculosis; ii) Strategies to Address HIV and HIV-associated Infections in Pediatric and Maternal Populations; iii) Integrated HIV Prevention Strategies; and iv) Microbicide Strategies to Prevent HIV infections, and 1.b. Contributing to the scientific leadership of the 4 future NIAID-sponsored Networks. 2. Utilizing an increasingly efficient and sophisticated centralized administrative structure to support the uninterrupted execution of protocols across 4 restructured CRSs, laboratory, and pharmacy components. 3. Leveraging the integral relationships developed with the CTU's community partners and diverse stakeholders to disseminate research findings and translate research results into evidence-based best practices and policies at the local, regional, and international levels.
The CTU's implementation of protocols across the 4 Networks may produce results that translate to policies within Zimbabwe and internationally to reduce HIV incidence and prevalence. The CTU anticipates that this new evidence will further inform policies to reduce the Zimbabwean HIV incidence from its current 3% to 2%; reduce current HIV prevalence from 13% to 7.5%; reduce HIV vertical transmission from the current 14% to <5%; and reduce TB incidence from 633 per 100,000 persons to 200 per 100,000.
|Uprety, Priyanka; Lindsey, Jane C; Levin, Myron J et al. (2017) Inflammation and Immune Activation in Antiretroviral-Treated Human Immunodeficiency Virus Type 1-Infected African Infants and Rotavirus Vaccine Responses. J Infect Dis 215:928-932|
|Chirenje, Zvavahera Mike; Gundacker, Holly M; Richardson, Barbra et al. (2017) Risk Factors for Incidence of Sexually Transmitted Infections Among Women in a Human Immunodeficiency Virus Chemoprevention Trial: VOICE (MTN-003). Sex Transm Dis 44:135-140|
|Palumbo, Philip J; Wilson, Ethan A; Piwowar-Manning, Estelle et al. (2017) Association of HIV diversity and virologic outcomes in early antiretroviral treatment: HPTN 052. PLoS One 12:e0177281|
|Riddler, Sharon A; Husnik, Marla; Ramjee, Gita et al. (2017) HIV disease progression among women following seroconversion during a tenofovir-based HIV prevention trial. PLoS One 12:e0178594|
|Akello, Carolyne A; Bunge, Katherine E; Nakabiito, Clemensia et al. (2017) Contraceptive Use and Pregnancy Incidence Among Women Participating in an HIV Prevention Trial. J Womens Health (Larchmt) 26:670-676|
|Tenforde, Mark W; Yadav, Ashish; Dowdy, David W et al. (2017) Vitamin A and D Deficiencies Associated With Incident Tuberculosis in HIV-Infected Patients Initiating Antiretroviral Therapy in Multinational Case-Cohort Study. J Acquir Immune Defic Syndr 75:e71-e79|
|Koss, Catherine A; Bacchetti, Peter; Hillier, Sharon L et al. (2017) Differences in Cumulative Exposure and Adherence to Tenofovir in the VOICE, iPrEx OLE, and PrEP Demo Studies as Determined via Hair Concentrations. AIDS Res Hum Retroviruses :|
|Balkus, Jennifer E; Brown, Elizabeth R; Hillier, Sharon L et al. (2016) Oral and injectable contraceptive use and HIV acquisition risk among women in four African countries: a secondary analysis of data from a microbicide trial. Contraception 93:25-31|
|Hosseinipour, Mina C; Bisson, Gregory P; Miyahara, Sachiko et al. (2016) Empirical tuberculosis therapy versus isoniazid in adult outpatients with advanced HIV initiating antiretroviral therapy (REMEMBER): a multicountry open-label randomised controlled trial. Lancet 387:1198-209|
|De Boni, Raquel B; Zheng, Lu; Rosenkranz, Susan L et al. (2016) Binge drinking is associated with differences in weekday and weekend adherence in HIV-infected individuals. Drug Alcohol Depend 159:174-80|
Showing the most recent 10 out of 38 publications